Soria, Francesco
Krabbe, Laura-Maria
Todenhöfer, Tilman
Dobruch, Jakub
Mitra, Anirban P.
Inman, Brant A.
Gust, Kilian M.
Lotan, Yair
Shariat, Shahrokh F. http://orcid.org/0000-0001-8443-8453
Article History
Received: 29 May 2018
Accepted: 20 September 2018
First Online: 26 September 2018
Compliance with ethical standards
:
: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer, granted 2002-09-06; methods to determine prognosis after therapy for bladder cancer, granted 2003-06-19; prognostic methods for patients with prostatic disease, granted 2004-08-05; soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma, granted 2010-07-20. He is an advisory board member of Astellas, Cepheid, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanofi, and Wolff. He is a speaker for Astellas, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanochemia, Sanofi and Wolff.
: This study was conducted according to the Declaration of Helsinki.